No Data
Regeneron Pharma Initiated at Neutral by Citigroup
28 Analysts Have This To Say About Regeneron Pharmaceuticals
Citi Upgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Raises Target Price to $895
Express News | Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at Ash
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight